Table 3 Overall survival of PD-L1, PD-1, CD8, CD4 and CD3 is shown for the derivation and validation cohorts.

From: Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

Derivation cohort			Validation cohort
Variables	Median OS (months)	p value	Variables	Median OS (months)	p value
Tumour PD-L1 expression		0.003	Tumour PD-L1 expression		0.73
<1% (n = 50)	5.0		<1% (n = 49)	6.0
1–49% (n = 8)	1.0		1–49% (n = 8)	6.0
≥50% (n = 8)	21.0		≥50% (n = 13)	8.0
Stromal infiltration of PD-L1⁺ IC		0.68	Stromal infiltration of PD-L1⁺ IC		0.72
Low infiltration (n = 40)	5.0		Low infiltration (n = 44)	6.0
Intermediate infiltration (n = 15)	7.0		Intermediate infiltration (n = 14)	9.0
High infiltration (n = 9)	5.0		High infiltration (n = 10)	9.0
Stromal infiltration of PD-1⁺ IC		0.080	Stromal infiltration of PD-1⁺ IC		0.13
Low infiltration (n = 38)	5.0		Low infiltration (n = 43)	6.0
Intermediate infiltration (n = 21)	9.0		Intermediate infiltration (n = 13)	6.0
High infiltration (n = 7)	NR		High infiltration (n = 14)	12.0
Tumour infiltration of CD8⁺ IC		0.062	Tumour infiltration of CD8⁺ IC		0.024
Low infiltration (n = 35)	5.0		Low infiltration (n = 41)	5.0
Intermediate infiltration (n = 18)	7.0		Intermediate infiltration (n = 9)	6.0
High infiltration (n = 14)	5.0		High infiltration (n = 20)	12.0
Stromal infiltration of CD8⁺ IC		0.035	Stromal infiltration of CD8⁺ IC		0.007
Low infiltration (n = 15)	5.0		Low infiltration (n = 14)	6.0
Intermediate infiltration (n = 21)	5.0		Intermediate infiltration (n = 24)	4.0
High infiltration (n = 30)	9.0		High infiltration (n = 32)	11.0
Stromal infiltration of CD3⁺ IC		0.017	Stromal infiltration of CD3⁺ IC		0.16
Low infiltration (n = 22)	3.0		Low infiltration (n = 27)	5.0
Intermediate infiltration (n = 21)	7.0		Intermediate infiltration (n = 28)	8.0
High infiltration (n = 22)	8.0		High infiltration (n = 15)	10.0
Stromal infiltration of CD4⁺ IC		0.010	Stromal infiltration of CD4⁺ IC		0.018
Low infiltration (n = 16)	5.0		Low infiltration (n = 15)	6.0
Intermediate infiltration (n = 13)	5.0		Intermediate infiltration (n = 23)	3.0
High infiltration (n = 36)	9.0		High infiltration (n = 32)	10.0
Combined tumour and stromal infiltration of CD8⁺ IC		<0.0001	Combined tumour and stromal infiltration of CD8⁺ IC		0.008
Low infiltration of tumour and stromal CD8⁺ IC (n = 28)	5.0		Low infiltration of tumour and stromal CD8⁺ IC (n = 31)	5.0
High infiltration of tumour or stromal CD8⁺ IC (n = 14)	2.0		High infiltration of tumour or stromal CD8⁺ IC (n = 17)	6.0
High infiltration of tumour and stromal CD8⁺ IC (n = 24)	12.0		High infiltration of tumour and stromal CD8⁺ IC (n = 22)	12.0
Combined stromal infiltration of PD-1⁺ and CD8⁺ IC		0.023	Combined stromal infiltration of PD-1⁺ and CD8⁺ IC		0.027
Low infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 28)	5.0		Low infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 33)	6.0
High infiltration of stromal PD-1⁺ or CD8⁺ IC (n = 17)	7.0		High infiltration of stromal PD-1⁺ or CD8⁺ IC (n = 15)	3.0
High infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 20)	9.0		High infiltration of stromal PD-1⁺ and CD8⁺ IC (n = 22)	12.0
Combined stromal infiltration of PD-L1⁺ and CD8⁺ IC		0.021	Combined stromal infiltration of PD-L1⁺ and CD8⁺ IC		0.18
Low infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 30)	5.0		Low infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 31)	5.0
High infiltration of stromal PD-L1⁺ or CD8⁺ IC (n = 16)	9.0		High infiltration of stromal PD-L1⁺ or CD8⁺ IC (n = 19)	6.0
High infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 18)	7.0		High infiltration of stromal PD-L1⁺ and CD8⁺ IC (n = 18)	12.0

Statistically significant p < 0.05 values are in bold

Back to article page

Table 3 Overall survival of PD-L1, PD-1, CD8, CD4 and CD3 is shown for the derivation and validation cohorts.

Search

Quick links